The facility of the future will be fully automated
The biopharma facility of the future will be fully automated comprising a critically enabling set of standardized and interoperable technologies and capabilities that will decrease capital and operating costs, reduce the time to build and commission facilities, resulting in a faster speed to market for drugs as well as a reduction in the total cost. The automated facility will be integrated from development to final drug product and will be able to deal with variable processes, variable batch sizes and variable geographies. To meet varying market demands it will be able to quickly ramp capacity up or down and do so with minimal staff, minimal time to change over, with maximum safety and minimum regulatory observations.
This is 1 of 8 roadmap documents, to download others click on the ‘First Edition Documents’ menu